Full-Time
Manager – Portfolio Strategy and Management
Updated on 9/3/2024
Tempus
1,001-5,000 employees
AI-driven healthcare data analysis platform
Senior, Expert
Chicago, IL, USA
- 5+ years of experience in a strategic business function such as corporate strategy, management consulting, private equity, and/or product management
- 3+ years of experience in the healthcare and/or life sciences sector
- Excellent verbal and written communication skills
- Entrepreneurial mindset and comfort with ambiguity
- Solutions-oriented and bias to action
- Develop long-term portfolio vision, strategy and roadmap for Tempus’ tissue biopsy products, based on analysis of customer needs, competitive landscape, internal feasibility, and financial and strategic value. Deliverables may include:
- 3-5 year business roadmaps, prioritizing new product and other business growth opportunities
- Target product profiles (TPPs)
- Commercialization and lifecycle management plans
- Collaborate with cross-functional leadership (sales, marketing, market access, medical, product, R&D, etc.) to deliver on business goals for the liquid biopsy portfolio
- Ensure appropriate resource availability and prioritization
- Constantly evaluate trade-off decisions to ensure product development speed, efficiency, and quality
- Develop launch strategies to guide new product launch planning
- Proactively monitor competitive intelligence and customer feedback to identify and act on new threats and opportunities
- Lead cross-functional annual planning process for the liquid portfolio
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.
Company Stage
Series G
Total Funding
$1.3B
Headquarters
Chicago, Illinois
Founded
2015
6 month growth
↑ 5%1 year growth
↑ 12%2 year growth
↑ 36%
Simplify's Take
What believers are saying
- Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
- Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
- The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.
What critics are saying
- The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
- Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.
What makes Tempus unique
- Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
- Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
- Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.